Literature DB >> 19568477

3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder.

Ana Cristina Andreazza1, Flavio Kapczinski, Marcia Kauer-Sant'Anna, Julio C Walz, David J Bond, Carlos A Gonçalves, L Trevor Young, Lakshmi N Yatham.   

Abstract

BACKGROUND: There has been an increasing interest in the role of oxidative stress in the pathophysiology of bipolar disorder. To explore this further, we evaluated the activity of glutathione peroxidase (GPx), glutathione reductase (GR) and glutathione S-transferase (GST), as well as 3-nitrotyrosine levels and carbonyl content in patients in the early (within 3 years of illness onset) and late (a minimum of 10 years of illness) stages of bipolar disorder.
METHODS: We matched 30 patients in the early stage and 30 patients in the late stage of bipolar disorder, diagnosed according to DSM-IV criteria, with 60 healthy controls (30 matched for each group of patients). We measured symptomatic status using the Hamilton Rating Scale for Depression and the Young Mania Rating Scale.
RESULTS: We found a significant increase in 3-nitrotyrosine levels among patients in the early (p < 0.010) and late (p < 0.010) stages of bipolar disorder. The activity of GR and GST was increased only among patients in the late stage of illness. Glutathione peroxidase activity and carbonyl content did not differ among the groups. LIMITATIONS: Limitations of our study include its cross-sectional design, which did not allow us to examine direct causative mechanisms or the effects of progression of illness, and the potential environmental bias introduced by comparing patient groups recruited from different regions of the world.
CONCLUSION: Our data indicate a possible tyrosine nitration-induced damage in patients with bipolar disorder that is present from the early stage of illness. Our data also indicate that patients in the late stage of illness demonstrate enhanced activity of GR and GST, which could suggest the involvement of a compensatory system in bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19568477      PMCID: PMC2702443     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  73 in total

1.  The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia.

Authors:  F M Benes; D Matzilevich; R E Burke; J Walsh
Journal:  Mol Psychiatry       Date:  2006-03       Impact factor: 15.992

2.  The increasing medical burden in bipolar disorder.

Authors:  David J Kupfer
Journal:  JAMA       Date:  2005-05-25       Impact factor: 56.272

Review 3.  Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment.

Authors:  B Halliwell
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes.

Authors:  S Baez; J Segura-Aguilar; M Widersten; A S Johansson; B Mannervik
Journal:  Biochem J       Date:  1997-05-15       Impact factor: 3.857

5.  Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania.

Authors:  Benicio N Frey; Samira S Valvassori; Gislaine Z Réus; Márcio R Martins; Fabrícia C Petronilho; Katrine Bardini; Felipe Dal-Pizzol; Flávio Kapczinski; João Quevedo
Journal:  J Psychiatry Neurosci       Date:  2006-09       Impact factor: 6.186

6.  Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections.

Authors:  T G Hastings; D A Lewis; M J Zigmond
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

7.  Possible role of nitric oxide and adrenomedullin in bipolar affective disorder.

Authors:  Haluk A Savaş; Hasan Herken; Muhittin Yürekli; Efkan Uz; Hamdi Tutkun; Süleyman Salih Zoroğlu; Murat Eren Ozen; Beyhan Cengiz; Omer Akyol
Journal:  Neuropsychobiology       Date:  2002       Impact factor: 2.328

Review 8.  Early intervention in bipolar disorders: clinical, biochemical and neuroimaging imperatives.

Authors:  Michael Berk; Gin S Malhi; Karen Hallam; Clarissa S Gama; Seetal Dodd; Ana Cristina Andreazza; Benício N Frey; Flavio Kapczinski
Journal:  J Affect Disord       Date:  2008-09-26       Impact factor: 4.839

9.  Molecular evidence for mitochondrial dysfunction in bipolar disorder.

Authors:  Christine Konradi; Molly Eaton; Matthew L MacDonald; John Walsh; Francine M Benes; Stephan Heckers
Journal:  Arch Gen Psychiatry       Date:  2004-03

10.  The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode.

Authors:  Salih Selek; Haluk A Savas; H Serdar Gergerlioglu; Feridun Bulbul; Efkan Uz; Mehmet Yumru
Journal:  J Affect Disord       Date:  2007-09-14       Impact factor: 4.839

View more
  58 in total

Review 1.  Antioxidants as antidepressants: fact or fiction?

Authors:  Giovanni Scapagnini; Sergio Davinelli; Filippo Drago; Antonino De Lorenzo; Giovannangelo Oriani
Journal:  CNS Drugs       Date:  2012-06-01       Impact factor: 5.749

2.  Metabolic imbalance associated with methylation dysregulation and oxidative damage in children with autism.

Authors:  Stepan Melnyk; George J Fuchs; Eldon Schulz; Maya Lopez; Stephen G Kahler; Jill J Fussell; Jayne Bellando; Oleksandra Pavliv; Shannon Rose; Lisa Seidel; David W Gaylor; S Jill James
Journal:  J Autism Dev Disord       Date:  2012-03

Review 3.  Staging bipolar disorder.

Authors:  Eduard Vieta; M Reinares; A R Rosa
Journal:  Neurotox Res       Date:  2010-05-12       Impact factor: 3.911

Review 4.  Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment.

Authors:  Trevor Archer; Richard M Kostrzewa; Tomas Palomo; Richard J Beninger
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

5.  Oxidative stress in early stage Bipolar Disorder and the association with response to lithium.

Authors:  Rafael T de Sousa; Carlos A Zarate; Marcus V Zanetti; Alana C Costa; Leda L Talib; Wagner F Gattaz; Rodrigo Machado-Vieira
Journal:  J Psychiatr Res       Date:  2013-12-06       Impact factor: 4.791

Review 6.  Stage managing bipolar disorder.

Authors:  Michael Berk; Lesley Berk; Seetal Dodd; Sue Cotton; Craig Macneil; Rothanthi Daglas; Philippe Conus; Andreas Bechdolf; Steven Moylan; Gin S Malhi
Journal:  Bipolar Disord       Date:  2013-06-20       Impact factor: 6.744

7.  Combined actions of blueberry extract and lithium on neurochemical changes observed in an experimental model of mania: exploiting possible synergistic effects.

Authors:  Luiza Spohr; Mayara Sandrielly Pereira Soares; Pathise Souto Oliveira; Bruna da Silveira de Mattos; Natália Pontes Bona; Nathalia Stark Pedra; Fernanda Cardoso Teixeira; Carlus Augustu Tavares do Couto; Vitor Clasen Chaves; Flávio Henrique Reginatto; Meibel Teixeira Lisboa; Anderson Schwingel Ribeiro; Claiton Leoneti Lencina; Francieli Moro Stefanello; Roselia Maria Spanevello
Journal:  Metab Brain Dis       Date:  2018-12-07       Impact factor: 3.584

8.  Severity of anxiety- but not depression- is associated with oxidative stress in Major Depressive Disorder.

Authors:  Lisa R Steenkamp; Christina M Hough; Victor I Reus; Felipe A Jain; Elissa S Epel; S Jill James; Alexandra E Morford; Synthia H Mellon; Owen M Wolkowitz; Daniel Lindqvist
Journal:  J Affect Disord       Date:  2017-05-06       Impact factor: 4.839

9.  Postnatal exposure to trichloroethylene alters glutathione redox homeostasis, methylation potential, and neurotrophin expression in the mouse hippocampus.

Authors:  Sarah J Blossom; Stepan Melnyk; Craig A Cooney; Kathleen M Gilbert; S Jill James
Journal:  Neurotoxicology       Date:  2012-03-07       Impact factor: 4.294

10.  Aging changes and medical complexity in late-life bipolar disorder: emerging research findings that may help advance care.

Authors:  Martha Sajatovic; Brent P Forester; Ariel Gildengers; Benoit H Mulsant
Journal:  Neuropsychiatry (London)       Date:  2013-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.